Takeda Pharmaceutical Co Ltd TKPHF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TKPHF is a good fit for your portfolio.
News
-
Ovid Therapeutics Shares Slide Premarket After Takeda's Soticlestat Setback
-
Takeda's Soticlestat Misses Goals in Phase 3 Epilepsy Studies
-
Former Takeda Employee Pleads Guilty to Defrauding Company
-
Takeda Gets CHMP Approval for Recombinant ADAMTS13
-
Alzheimer's vaccine licensing deal boosts AC Immune
-
AC Immunity Shares Soar on Exclusive License Deal with Takeda
-
Takeda Pharmaceutical Projects Lower Annual Profit After Quarterly Loss — Update
-
Takeda Pharmaceutical Projects Lower Annual Profit After Quarterly Loss
Trading Information
- Previous Close Price
- $27.50
- Day Range
- $26.25–26.25
- 52-Week Range
- $23.80–32.76
- Bid/Ask
- $26.45 / $29.00
- Market Cap
- $41.60 Bil
- Volume/Avg
- 112 / 28,088
Key Statistics
- Price/Earnings (Normalized)
- 14.20
- Price/Sales
- 1.39
- Dividend Yield (Trailing)
- 4.71%
- Dividend Yield (Forward)
- 4.92%
- Total Yield
- 4.75%
Company Profile
Takeda Pharmaceutical is Japan’s largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company’s five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Large Core
- Total Number of Employees
- 49,281
- Website
- https://www.takeda.com
Competitors
Valuation
Metric
|
TKPHF
|
4519
|
4568
|
---|---|---|---|
Price/Earnings (Normalized) | 14.20 | 32.93 | 55.42 |
Price/Book Value | 0.85 | 5.88 | 6.43 |
Price/Sales | 1.39 | 9.50 | 6.78 |
Price/Cash Flow | 6.78 | 26.24 | 41.44 |
Price/Earnings
TKPHF
4519
4568
Financial Strength
Metric
|
TKPHF
|
4519
|
4568
|
---|---|---|---|
Quick Ratio | 0.51 | 4.02 | 2.32 |
Current Ratio | 1.11 | 5.09 | 3.01 |
Interest Coverage | 1.35 | — | 35.14 |
Quick Ratio
TKPHF
4519
4568
Profitability
Metric
|
TKPHF
|
4519
|
4568
|
---|---|---|---|
Return on Assets (Normalized) | 5.19% | 18.61% | 6.99% |
Return on Equity (Normalized) | 11.01% | 22.00% | 12.93% |
Return on Invested Capital (Normalized) | 7.28% | 21.98% | 10.69% |
Return on Assets
TKPHF
4519
4568
Drug Manufacturers - Specialty & Generic Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Zoetis Inc Class A
ZTS
| Ltwljffblh | Fcfkl | $82.5 Bil | |||
Merck KGaA ADR
MKKGY
| Xvfmpslkt | Rlldr | $73.2 Bil | |||
Haleon PLC ADR
HLN
| Qmwjvjdj | Vlpl | $41.0 Bil | |||
Teva Pharmaceutical Industries Ltd ADR
TEVA
| Pcqnwjxjh | Fmsl | $19.2 Bil | |||
Viatris Inc
VTRS
| Svnfwvd | Yqfnm | $14.0 Bil | |||
Dr Reddy's Laboratories Ltd ADR
RDY
| Dwlpccw | Vghq | $13.6 Bil | |||
Catalent Inc
CTLT
| Wjbbmwg | Vnllrr | $10.6 Bil | |||
Perrigo Co PLC
PRGO
| Wmgdccxl | Kwhsx | $3.8 Bil | |||
Prestige Consumer Healthcare Inc
PBH
| Svbccdrl | Wldpj | $3.5 Bil | |||
Curaleaf Holdings Inc
CURLF
| Jflqbzfjc | Bhpv | $3.0 Bil |